STRO Sutro Biopharma, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 12, 2026
$15.35
· of 52w range
· above low
· to high
$0.7752w low
$43.8552w high
Market Cap (MRQ)
$254M
P/E (TTM)
-0.6
EPS (TTM)
$-26.71
Revenue (TTM)
$46M
your badges
52W Range
$1–$44
Analyst Rating
BUY
Price Target
$47
P/E
-0.6
ROE
266.8%
Net Profit Margin
-395.2%
Your badge strip is empty — pin a metric anywhere on this page.
STRO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$15.35
Market Cap (MRQ)
$254M
P/E (TTM)
-0.6
EPS (TTM)
$-26.71
Revenue (TTM)
$46M
ROE (TTM)
266.8%
52W Range
$1–$44
STRO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Dec. 3, 2025 | 1-for-10 | Reverse |
About Sutro Biopharma, Inc. - Common Stock Company overview from Wikipedia
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.
As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically validated targets for which the current standard of care is suboptimal.
Technology
Sutro's Xpress CF Platform is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology. XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins. The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs). Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over US$170 million in capital.
Collaborations
In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).
Awards
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014. In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees128
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$102M2016-12-31 → 2025-12-31
EPS$-22.492020-12-31 → 2025-12-31
Free Cash Flow·2018-12-31 → 2018-12-31
Net margin-395.2%2018-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | STRO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -0.65Y avg ≈-2.6 | ≈-2.6 | · | · | |
| P/S (TTM) | 5.65Y avg ≈4.6 | ≈4.6 | 48.5 | Undervalued | |
| P/B (MRQ) | -2.55Y avg ≈1.9 | ≈1.9 | · | · | |
| Price / Cash Flow | -0.75Y avg ≈23.8 | ≈23.8 | · | · | |
| Price / Tangible Book | 4.55Y avg ≈2.5 | ≈2.5 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | STRO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -319.6%5Y avg ≈-189.3% | ≈-189.3% | -871.1% | Top tier | |
| EBITDA Margin (TTM) | -306.3%5Y avg ≈-181.4% | ≈-181.4% | -871.1% | Top tier | |
| Pretax Margin (TTM) | -395.5%5Y avg ≈-194.8% | ≈-194.8% | -196.5% | Weak | |
| Net Profit Margin (TTM) | -395.2%5Y avg ≈-193.8% | ≈-193.8% | -871.2% | Top tier | |
| ROA (TTM) | -79.1%5Y avg ≈-41.2% | ≈-41.2% | -39.4% | Weak | |
| ROE (TTM) | 266.8%5Y avg ≈-46.8% | ≈-46.8% | -45.3% | Top tier | |
| ROIC | 119.5%5Y avg ≈-136.8% | ≈-136.8% | -19.2% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | STRO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 3.35Y avg ≈3.9 | ≈3.9 | 6.3 | Low liquidity | |
| Quick Ratio (MRQ) | 3.25Y avg ≈3.4 | ≈3.4 | 4.9 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | STRO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 65.2%5Y avg ≈37.3% | ≈37.3% | · | · | |
| Revenue CAGR 3Y | 14.8%5Y avg ≈22.7% | ≈22.7% | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | STRO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.45Y avg ≈0.2 | ≈0.2 | 0.0 | Top tier | |
| Receivables Turnover | 16.35Y avg ≈8.0 | ≈8.0 | 3.9 | Top tier | |
| Revenue / Employee | ≈$800.7K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-3.4%
Next Report
Nov 04, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 5, 2026 | $-2.33 | $-2.24 | -4.1% |
| March 31, 2026 | May 14, 2026 | $-2.94 | $-3.85 | 23.6% |
| Dec. 31, 2025 | $-5.29 | $-4.43 | -19.4% | |
| Sept. 30, 2025 | $-6.70 | $-4.23 | -58.5% | |
| June 30, 2025 | $-1.40 | $-4.10 | 65.9% | |
| March 31, 2025 | $-9.10 | $-7.22 | -26.1% | |
| Dec. 31, 2024 | $-8.90 | $-8.48 | -5.0% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | |
| R&D Expense | $166M | $252M | $180M | $137M | $104M | $77M | $66M | $54M | $55M | |
| SG&A Expense | $41M | $48M | $63M | $60M | $56M | $37M | $33M | $21M | $16M | |
| Operating Expenses | $261M | $300M | $243M | $197M | $160M | $114M | $98M | $76M | $71M | |
| Operating Income | $-158M | $-238M | $-89M | $-129M | $-99M | $-71M | $-55M | $-37M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $612.0K | |
| Other Non-op | · | · | · | · | · | · | · | $2M | $-77.0K | |
| Pretax Income | $-191M | $-225M | $-89M | $-117M | $-106M | $-32M | · | · | · | |
| Income Tax | $-93.0K | $2M | $18M | $2M | $0 | $103.0K | $0 | $0 | $0 | |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | $-20M | |
| EPS (Basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| Shares (Basic) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| Shares (Diluted) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| EBITDA | $-151M | $-231M | $-82M | $-123M | $-94M | $-67M | · | $-33M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $190M | $69M | $47M | $30M | $206M | $5M | $125M | $22M | |
| Short-term Investments | $83M | $127M | $264M | $255M | $130M | $120M | $113M | $79M | · | |
| Receivables | $4M | $9M | $36M | $7M | $12M | $6M | $6M | $2M | $2M | |
| Prepaid Expense | $6M | $18M | $10M | $12M | $8M | $4M | $4M | $3M | $2M | |
| Current Assets | $151M | $343M | $422M | $353M | $219M | $378M | $129M | $210M | $26M | |
| PP&E (Net) | $11M | $18M | $22M | $25M | $23M | $13M | $10M | $11M | $14M | |
| PP&E (Gross) | $38M | $67M | $64M | $63M | $56M | $50M | $43M | $40M | $39M | |
| Accum. Depreciation | $27M | $49M | $42M | $38M | $33M | $37M | $34M | $29M | $25M | |
| Other Non-current Assets | $495.0K | $7M | $4M | $2M | $2M | $2M | $3M | $2M | $1M | |
| Total Assets | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Accounts Payable | $8M | $10M | $9M | $5M | $6M | $6M | $6M | $3M | $3M | |
| Accrued Liabilities | $15M | $13M | $15M | $13M | $11M | $9M | $6M | $6M | $4M | |
| Current Liabilities | $75M | $132M | $94M | $67M | $42M | $30M | $33M | $36M | $32M | |
| Capital Leases | $8M | $16M | $23M | $30M | $31M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $119.0K | $146.0K | $481.0K | $134.0K | $102.0K | $14.0K | |
| Total Liabilities | $306M | $343M | $321M | $190M | $89M | $62M | $59M | $92M | $47M | |
| Long-term Debt | · | · | $4M | $16M | $25M | $25M | · | $15M | · | |
| Total Debt | · | · | $4M | $16M | $25M | $25M | · | $10M | · | |
| Common Stock | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K | $46.0K | $23.0K | $23.0K | · | |
| Retained Earnings | $-978M | $-787M | $-559M | $-453M | $-333M | $-228M | $-196M | $-150M | $-115M | |
| AOCI | $19.0K | $39.0K | $21.0K | $-618.0K | $-314.0K | $129.0K | $165.0K | $-47.0K | · | |
| Stockholders' Equity | $-132M | $45M | $150M | $217M | $253M | $332M | $98M | $132M | $-109M | |
| Liabilities + Equity | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Shares Outstanding | 8,584,309 | 8,306,398 | 61,009,829 | 57,499,541 | 46,327,131 | 45,752,116 | 23,098,969 | 22,848,184 | 465,330 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $7M | $6M | $5M | $4M | $5M | $5M | $5M | |
| Stock-based Comp | $14M | $25M | $25M | $26M | $23M | $12M | $10M | $3M | $1M | |
| Restructuring | $13M | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-7M | $4M | $-37M | $91M | $-4M | $-52M | · | $41M | · | |
| Operating Cash Flow | $-177M | $-192M | $-112M | $4M | $-82M | $-68M | $-65M | $13M | $-37M | |
| CapEx | · | · | · | · | · | · | · | $2M | $3M | |
| Investing Cash Flow | $45M | $219M | $-4M | $-35M | $-97M | $604.0K | $-51M | $-80M | $33M | |
| Debt Issued | · | · | · | · | · | · | · | $0 | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | $0 | $25M | $0 | $0 | · | $251M | $-327.0K | · | · | |
| Stock Repurchased | · | · | · | · | $7.0K | · | · | · | · | |
| Net Stock Activity | $0 | $25M | $12M | $56M | $-7.0K | $251M | · | · | · | |
| Financing Cash Flow | $44.0K | $94M | $138M | $48M | $3M | $269M | $-4M | $171M | $15M | |
| Net Change in Cash | $-132M | $121M | $22M | $17M | $-176M | $202M | $-120M | $103M | $10M | |
| Taxes Paid | $75.0K | $18M | $379.0K | $0 | $103.0K | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | $11M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | · | -96.9% | · | |
| Net Margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | · | -91.9% | · | |
| Pretax Margin | -186.5% | -362.8% | -57.6% | -172.2% | · | · | · | · | · | |
| EBITDA Margin | -147.4% | -372.7% | -53.6% | -181.9% | -151.4% | -156.3% | · | -85.1% | · | |
| ROA | -68.1% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | · | -26.8% | · | |
| ROE | 232.2% | -292.0% | -81.5% | -53.4% | -39.4% | -11.2% | · | 713.8% | · | |
| ROIC | 119.5% | -540.2% | -70.0% | -56.5% | · | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 | 12.8 | · | 5.8 | · | |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 | 11.2 | · | 5.7 | · | |
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 | 0.1 | · | 0.1 | · | |
| LT Debt / Equity | · | · | 0.0 | 0.0 | 0.1 | 0.1 | · | 0.1 | · | |
| Interest Coverage | · | · | · | · | · | · | · | -22.9 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | |
| Receivables Turnover | 16.3 | 2.8 | 7.1 | 6.9 | 6.9 | 7.2 | · | 18.7 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-15.43 | $0.54 | $2.45 | $3.77 | $5.45 | $7.26 | · | $5.76 | · | |
| Revenue / Share | $12.06 | $0.81 | $2.56 | $1.34 | · | · | · | · | · | |
| Cash Flow / Share | $-20.86 | $-2.49 | $-1.86 | $0.07 | · | · | · | · | · | |
| Cash / Share | $6.77 | $2.31 | $1.14 | $0.82 | $0.66 | $4.51 | · | $5.48 | · | |
| EPS (TTM) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 0.09% | 53.2% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | · | |
| Net Income TTM | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | · | |
| Market Cap | $99M | $152M | $262M | $465M | $689M | $993M | · | $206M | · | |
| Enterprise Value | · | · | $-68M | $179M | $554M | $691M | · | $12M | · | |
| P/E | -0.5 | -0.1 | -2.4 | -3.4 | -6.5 | -21.9 | · | · | · | |
| P/S | 1.0 | 2.4 | 1.7 | 6.9 | 11.1 | 23.2 | · | 5.4 | · | |
| P/B | -0.7 | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | 1.6 | · | |
| P / Tangible Book | · | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | · | · | |
| P / Cash Flow | -0.6 | -0.8 | -2.3 | 130.9 | -8.4 | -14.6 | · | 16.2 | · | |
| P / FCF | · | · | · | · | · | · | · | 18.5 | · | |
| EV / EBITDA | · | · | 0.8 | -1.4 | -5.9 | -10.4 | · | -0.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | 1.0 | · | |
| EV / Revenue | · | · | -0.4 | 2.6 | 8.9 | 16.2 | · | 0.3 | · | |
| Earnings Yield | -194.4% | -1597.8% | -41.5% | -29.1% | -15.4% | -4.6% | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $12M | $10M | $64M | $17M | $15M | $9M | $26M | $13M | $114M | $17M | $10M | $13M | $25M | $28M | |
| R&D Expense | $32M | $37M | $37M | $40M | $38M | $52M | $71M | $62M | $62M | $57M | $54M | $46M | $42M | $39M | $32M | $32M | |
| SG&A Expense | $8M | $8M | $9M | $9M | $10M | $13M | $9M | $14M | $12M | $13M | $17M | $15M | $15M | $16M | $15M | $15M | |
| Operating Expenses | $40M | $44M | $50M | $58M | $67M | $86M | $80M | $76M | $74M | $70M | $71M | $61M | $57M | $55M | $46M | $47M | |
| Operating Income | $-30M | $-30M | $-38M | $-48M | $-3M | $-69M | $-65M | $-68M | $-49M | $-57M | $43M | $-44M | $-46M | $-42M | $-21M | $-19M | |
| Pretax Income | $-39M | $-38M | $-47M | $-57M | $-12M | $-76M | $-70M | $-49M | $-48M | $-58M | $47M | $-47M | $-38M | $-50M | $-19M | $-24M | |
| Income Tax | $1.0K | $-15.0K | $-82.0K | $0 | $-18.0K | $7.0K | $2M | $0 | $8.0K | · | $16M | $2M | $151.0K | $395.0K | $0 | $2M | |
| Net Income | $-39M | $-38M | $-47M | $-57M | $-11M | $-76M | $-72M | $-49M | $-48M | $-58M | $31M | $-49M | $-39M | $-50M | $-19M | $-26M | |
| EPS (Basic) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.37 | $-0.55 | |
| EPS (Diluted) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.37 | $-0.55 | |
| Shares (Basic) | 16,571,602 | 13,082,355 | · | 84,869,864 | 8,511,985 | 8,364,294 | · | 82,043,671 | 81,224,628 | 61,457,793 | · | 60,599,025 | 60,339,475 | 58,723,432 | 52,345,732 | 46,957,196 | |
| Shares (Diluted) | 16,571,602 | 13,082,355 | · | 84,869,864 | 8,511,985 | 8,364,294 | · | 82,043,671 | 81,224,628 | 61,457,793 | · | 60,599,025 | 60,339,475 | 58,723,432 | 52,345,732 | 46,957,196 | |
| EBITDA | $-30M | $-28M | · | $-48M | $-3M | $-67M | · | $-68M | $-49M | $-55M | · | $-44M | $-46M | $-41M | $-21M | $-19M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $74M | $58M | $66M | $64M | $106M | $190M | $175M | $91M | $65M | $69M | $82M | $235M | $62M | $97M | $79M | |
| Short-term Investments | $110M | $129M | $83M | $102M | $141M | $143M | $127M | $214M | $285M | $202M | $264M | $239M | $123M | $189M | $191M | $113M | |
| Receivables | $6M | $12M | $4M | $4M | $8M | $14M | $9M | $7M | $7M | $31M | $36M | $17M | $10M | $10M | $11M | $98M | |
| Prepaid Expense | $6M | $6M | $6M | $11M | $18M | $25M | $18M | $11M | $11M | $10M | $10M | $9M | $10M | $18M | $11M | $8M | |
| Current Assets | $176M | $221M | $151M | $182M | $232M | $287M | $343M | $406M | $443M | $355M | $422M | $381M | $412M | $304M | $347M | $332M | |
| PP&E (Net) | $8M | $9M | $11M | $13M | $15M | $17M | $18M | $19M | $19M | $21M | $22M | $22M | $24M | $24M | $24M | $24M | |
| PP&E (Gross) | · | · | $38M | · | · | · | $67M | · | · | · | $64M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $27M | · | · | · | $49M | · | · | · | $42M | · | · | · | · | · | |
| Other Non-current Assets | $1M | $1M | $495.0K | $0 | $50.0K | $85.0K | $7M | $7M | $5M | $6M | $4M | $3M | $3M | $3M | $2M | $2M | |
| Total Assets | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | $401M | $386M | |
| Accounts Payable | $3M | $5M | $8M | $7M | $4M | $8M | $10M | $6M | $6M | $8M | $9M | $6M | $4M | $5M | $12M | $13M | |
| Accrued Liabilities | $6M | $5M | $15M | $13M | $12M | $12M | $13M | $13M | $10M | $7M | $15M | $11M | $10M | $6M | $10M | $8M | |
| Current Liabilities | $53M | $71M | $75M | $72M | $74M | $133M | $132M | $131M | $130M | $80M | $94M | $74M | $67M | $59M | $58M | $45M | |
| Capital Leases | $4M | $6M | $8M | $10M | $12M | $14M | $16M | $18M | $20M | $21M | $23M | $25M | $27M | $28M | $31M | $32M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | · | $133.0K | $142.0K | |
| Total Liabilities | $298M | $309M | $306M | $297M | $294M | $347M | $343M | $341M | $337M | $305M | $321M | $319M | $310M | $173M | $171M | $177M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7M | $10M | |
| Common Stock | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K | $82.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | $55.0K | $49.0K | |
| Retained Earnings | $-1.05B | $-1.02B | $-978M | $-931M | $-874M | $-863M | $-787M | $-714M | $-666M | $-618M | $-559M | $-590M | $-541M | $-503M | $-418M | $-399M | |
| AOCI | $-58.0K | $-101.0K | $19.0K | $33.0K | $-13.0K | $-9.0K | $39.0K | $106.0K | $-163.0K | $-113.0K | $21.0K | $7.0K | $16.0K | $-107.0K | $-1M | $-1M | |
| Stockholders' Equity | $-103M | $-67M | $-132M | $-87M | $-32M | $-26M | $45M | $111M | $152M | $98M | $150M | $112M | $155M | $185M | $230M | $209M | |
| Liabilities + Equity | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | $401M | $386M | |
| Shares Outstanding | 16,576,205 | 16,566,803 | 8,584,309 | 85,101,749 | 84,720,047 | 84,349,041 | 8,306,398 | 82,395,350 | 81,861,584 | 62,456,546 | 61,009,829 | 60,900,704 | 60,471,041 | 60,161,801 | 54,631,360 | 48,674,232 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $5M | $6M | $6M | $7M | $6M | $6M | $6M | $6M | $7M | $6M | $7M | $7M | |
| Restructuring | · | $0 | $1M | $3M | $1M | $8M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-7M | · | · | · | $647.0K | · | · | · | $-14M | · | · | · | $-19M | · | · | |
| Operating Cash Flow | $-38M | $-42M | $-26M | $-38M | $-45M | $-68M | $-72M | $-65M | $9M | $-65M | $14M | $-34M | $-31M | $-61M | $66M | $-3M | |
| Investing Cash Flow | $19M | $-45M | $19M | $40M | $3M | $-16M | $87M | $147M | $-80M | $64M | $-24M | $-114M | $66M | $67M | $-78M | $48M | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-418.0K | $103M | $-64.0K | $102.0K | $-60.0K | $66.0K | $-24.0K | $1M | $96M | $-3M | $-3M | $-6M | $138M | $9M | $30M | $5M | |
| Net Change in Cash | $-19M | $16M | $-8M | $2M | $-42M | $-84M | $16M | $84M | $26M | $-4M | $-13M | $-153M | $173M | $15M | $18M | $50M | |
| Taxes Paid | $1.0K | $-15.0K | $64.0K | $0 | $4.0K | $7.0K | $2M | $2.0K | $15M | $10.0K | · | · | · | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -303.8% | -204.2% | · | -499.9% | -5.2% | -393.8% | · | -797.2% | -189.4% | -435.1% | · | -260.1% | -443.5% | -333.3% | -84.3% | -69.0% | |
| Net Margin | -391.6% | -265.0% | · | -586.6% | -18.0% | -436.6% | · | -572.6% | -186.8% | -447.5% | · | -291.2% | -370.0% | -394.9% | -77.5% | -92.6% | |
| Pretax Margin | -391.6% | -265.1% | · | -586.6% | -18.1% | · | · | -572.6% | -186.8% | -447.5% | · | -280.3% | -368.6% | -391.8% | -77.5% | -83.7% | |
| EBITDA Margin | -303.8% | -195.4% | · | -499.9% | -5.2% | -382.9% | · | -797.2% | -189.4% | -421.5% | · | -260.1% | -443.5% | -320.5% | -84.3% | -69.0% | |
| ROA | -16.9% | -13.7% | · | -17.2% | -3.1% | -21.0% | · | -11.0% | -10.1% | -15.3% | · | -11.8% | -9.1% | -15.1% | -5.1% | -7.0% | |
| ROE | 56.9% | 83.0% | · | -474.8% | -19.1% | -210.4% | · | -43.6% | -31.3% | -41.1% | · | -28.8% | -21.2% | -24.7% | -7.6% | -10.1% | |
| ROIC | 28.9% | 44.3% | · | 55.5% | 10.4% | · | · | -61.1% | -32.0% | · | · | -40.7% | -30.0% | -23.0% | · | -9.8% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.1 | · | 2.5 | 3.1 | 2.2 | · | 3.1 | 3.4 | 4.5 | · | 5.2 | 6.1 | 5.1 | 5.9 | 7.4 | |
| Quick Ratio | 3.2 | 3.0 | · | 2.4 | 2.9 | 2.0 | · | 3.0 | 2.9 | 3.8 | · | 4.6 | 5.5 | 4.4 | 5.1 | 6.5 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.2 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | |
| Receivables Turnover | 1.4 | 1.1 | · | 1.8 | 8.5 | 0.8 | · | 0.7 | 3.0 | 0.6 | · | 1.2 | 0.2 | 1.2 | 2.1 | 0.5 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-6.23 | $-4.04 | · | $-1.03 | $-0.38 | $-0.31 | · | $1.35 | $1.86 | $1.57 | · | $1.84 | $2.56 | $3.08 | $4.21 | $4.29 | |
| Revenue / Share | $0.59 | $1.11 | · | $0.11 | $0.75 | $0.21 | · | $0.10 | $0.32 | $0.21 | · | $0.28 | $0.17 | $0.22 | $0.48 | $0.60 | |
| Cash Flow / Share | · | $-3.23 | · | · | · | $-0.82 | · | · | · | $-1.05 | · | · | · | $-1.04 | · | · | |
| Cash / Share | $3.28 | $4.45 | · | $0.77 | $0.76 | $1.26 | · | $2.12 | $1.11 | $1.04 | · | $1.34 | $3.89 | $1.04 | $1.77 | $1.63 | |
| EPS (TTM) | $-26.71 | $-25.73 | · | $-38.73 | $-38.65 | $-37.89 | · | $-1.25 | $-1.47 | $-1.52 | · | $-2.89 | $-2.45 | $-2.36 | $-2.59 | $-2.89 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $46M | $100M | · | $106M | $104M | $66M | · | $161M | $169M | $154M | · | $49M | $57M | $75M | $70M | $53M | |
| Net Income TTM | $-181M | $-154M | · | $-217M | $-209M | $-245M | · | $-124M | $-124M | $-115M | · | $-172M | $-143M | $-130M | $-123M | $-134M | |
| Market Cap | $550M | $413M | · | $74M | $60M | $55M | · | $285M | $240M | $353M | · | $211M | $281M | $278M | $303M | $254M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $23M | $72M | |
| P/E | -1.2 | -1.0 | · | -0.0 | -0.0 | -0.0 | · | -2.8 | -2.0 | -3.7 | · | -1.2 | -1.9 | -2.0 | -2.1 | -1.8 | |
| P/S | 12.0 | 4.1 | · | 0.7 | 0.6 | 0.8 | · | 1.8 | 1.4 | 2.3 | · | 4.3 | 4.9 | 3.7 | 4.3 | 4.8 | |
| P/B | -5.3 | -6.2 | · | -0.8 | -1.9 | -2.1 | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | 1.3 | 1.2 | |
| P / Tangible Book | · | · | · | · | · | · | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | 1.3 | 1.2 | |
| P / Cash Flow | · | -9.8 | · | · | · | -0.8 | · | · | · | -5.5 | · | · | · | -4.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.3 | 1.3 | |
| Earnings Yield | -80.5% | -103.3% | · | -4451.7% | -5443.7% | -5829.2% | · | -36.1% | -50.2% | -26.9% | · | -83.3% | -52.7% | -51.1% | -46.7% | -55.5% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M |
| Operating Margin % | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M |
| Diluted EPS | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 |
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 |
No data for this statement
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 110 filers · $537.9M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
110
Value held
$537.9M
New positions
43
Exited positions
16
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 43 (+15 vs prior Q) | 16 (+8 vs prior Q) | 23 (+1 vs prior Q) | 19 (+6 vs prior Q) | +2.1M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43,320,887 | 1,304,846 | 8.05% | Shares |
| BVF INC/IL | $41,559,362 | 1,251,788 | 7.73% | Shares |
| Affinity Asset Advisors, LLC | $38,926,568 | 1,172,487 | 7.24% | Shares |
| BlackRock, Inc. | $37,272,146 | 1,122,655 | 6.93% | Shares |
| SAMSARA BIOCAPITAL, LLC | $35,287,350 | 1,062,872 | 6.56% | Shares |
| Kynam Capital Management, LP | $28,968,926 | 872,558 | 5.39% | Shares |
| ORBIMED ADVISORS LLC | $24,698,941 | 743,944 | 4.59% | Shares |
| Balyasny Asset Management L.P. | $23,610,578 | 711,162 | 4.39% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $23,048,071 | 694,219 | 4.28% | Shares |
| EVENTIDE ASSET MANAGEMENT, LLC | $19,430,698 | 585,262 | 3.61% | Shares |
| Velan Capital Investment Management LP | $17,003,712 | 512,160 | 3.16% | Shares |
| Woodline Partners LP | $15,206,563 | 458,029 | 2.83% | Shares |
| ADAR1 Capital Management, LLC | $13,413,265 | 404,014 | 2.49% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $12,940,982 | 389,692 | 2.41% | Shares |
| MILLENNIUM MANAGEMENT LLC | $12,150,270 | 365,972 | 2.26% | Shares |
| STATE STREET CORP | $10,158,503 | 305,979 | 1.89% | Shares |
| Merck & Co., Inc. | $9,042,053 | 272,351 | 1.68% | Shares |
| ACUTA CAPITAL PARTNERS, LLC | $8,972,333 | 270,251 | 1.67% | Shares |
| AMERIPRISE FINANCIAL INC | $8,123,011 | 244,669 | 1.51% | Shares |
| Point72 Asset Management, L.P. | $7,895,856 | 237,827 | 1.47% | Shares |
| KVP Capital Advisors, LP | $7,522,290 | 226,575 | 1.40% | Shares |
| UBS Group AG | $6,922,599 | 208,512 | 1.29% | Shares |
| TWO SIGMA INVESTMENTS, LP | $6,696,042 | 201,688 | 1.24% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6,559,058 | 197,562 | 1.22% | Shares |
| MARSHALL WACE, LLP | $5,818,167 | 175,246 | 1.08% | Shares |
| Nuveen, LLC | $5,577,500 | 167,997 | 1.04% | Shares |
| JPMORGAN CHASE & CO | $5,323,560 | 159,627 | 0.99% | Shares |
| GOLDMAN SACHS GROUP INC | $4,953,971 | 149,216 | 0.92% | Shares |
| VANGUARD GROUP INC | $4,347,844 | 375,786 | 0.81% | Shares |
| NORTHERN TRUST CORP | $4,180,976 | 125,933 | 0.78% | Shares |
| Seven Fleet Capital Management LP | $3,794,182 | 159,118 | 0.71% | Shares |
| Qube Research & Technologies Ltd | $3,539,452 | 106,610 | 0.66% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $3,460,502 | 104,232 | 0.64% | Shares |
| CITADEL ADVISORS LLC | $3,385,238 | 101,965 | 0.63% | Shares |
| MACKENZIE FINANCIAL CORP | $3,146,264 | 94,767 | 0.58% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $2,865,957 | 86,324 | 0.53% | Shares |
| Invesco Ltd. | $1,902,526 | 57,305 | 0.35% | Shares |
| Y-Intercept (Hong Kong) Ltd | $1,855,183 | 55,879 | 0.34% | Shares |
| Squarepoint Ops LLC | $1,843,895 | 55,539 | 0.34% | Shares |
| XTX Topco Ltd | $1,732,011 | 52,169 | 0.32% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1,636,826 | 49,302 | 0.30% | Shares |
| Sigma Planning Corp | $1,494,664 | 45,020 | 0.28% | Shares |
| Bank of New York Mellon Corp | $1,373,451 | 41,369 | 0.26% | Shares |
| BARCLAYS PLC | $1,226,872 | 36,954 | 0.23% | Shares |
| BANK OF AMERICA CORP /DE/ | $1,199,848 | 36,140 | 0.22% | Shares |
| Fisher Asset Management, LLC | $1,171,794 | 35,295 | 0.22% | Shares |
| Elmind Capital, LP | $1,063,628 | 32,037 | 0.20% | Shares |
| D. E. Shaw & Co., Inc. | $1,000,250 | 30,128 | 0.19% | Shares |
| Trexquant Investment LP | $917,515 | 27,636 | 0.17% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $909,116 | 27,383 | 0.17% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., ILSF III, LLC, International Life Sciences Fund III (GP), L.P., International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Strategic Partners, L.P. | Oct. 9, 2018 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 30 insiders · 16 officers · 15 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jane Chung | Chief Executive Officer | March 4, 2026 M | 21,285 | 1 | 0 | $10,000 |
| William J Newell | CEO | March 5, 2025 M | 292,531 | 0 | 0 | $0 |
| Gregory K. Chow | CFO | June 2, 2026 M | 4,725 | 1 | 0 | $15,998 |
| Edward C Albini | CFO AND SECRETARY | May 15, 2025 M | 160,805 | 0 | 0 | $0 |
| Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | Sept. 18, 2026 M | 12,367 | 1 | 0 | $13,600 |
| David Pauling | Chief Admin. Ofcr. & GC | March 4, 2026 M | 9,748 | 1 | 0 | $10,003 |
| Barbara Leyman | Chief Business Officer | July 8, 2025 M | 16,056 | 0 | 0 | $0 |
| Venkatesh Srinivasan | CHIEF TECH OP OFFICER | May 1, 2025 M | 53,686 | 0 | 0 | $0 |
| Anne Elizabeth Borgman | CHIEF MEDICAL OFFICER | May 1, 2025 M | 97,452 | 0 | 0 | $0 |
| Linda A Fitzpatrick | CHIEF PEOPLE & COMM. OFFICER | May 1, 2025 M | 119,744 | 0 | 0 | $0 |
| Nicki Vasquez | CHIEF PORT. STRAT & ALNCE OFCR | Jan. 29, 2024 M | 14,279 | 0 | 0 | $0 |
| Brunilda Shtylla | Chief Business Officer | Aug. 28, 2023 S | 0 | 0 | 0 | $0 |
| Trevor Hallam | Pres. Rsrch & Cf. Sctific Ofcr | April 14, 2023 M | 100,368 | 0 | 0 | $0 |
| Anik Shabbir | Chief Technical Ops. Officer | March 3, 2023 M | 40,827 | 0 | 0 | $0 |
| Arturo Molina MD | Chief Medical Officer | March 5, 2022 M | 37,736 | 0 | 0 | $0 |
| Stephen Worsley | Chief Business Officer | Jan. 29, 2019 A | · | 0 | 0 | $0 |
| Heidi Hunter | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Michael Dybbs | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Jon Marc Wigginton | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Sukhi Jagpal | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Joseph M Lobacki | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Daniel H Petree | Director | June 5, 2026 A | 18,601 | 0 | 0 | $0 |
| Connie Matsui | Director | June 5, 2026 A | 50,000 | 1 | 0 | $40,000 |
| James P Panek | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| John Gordon Freund | Director | June 6, 2024 A | 56,327 | 0 | 0 | $0 |
| Shalini Sharp | Director | June 6, 2022 A | · | 0 | 0 | $0 |
| Daniel Janney | Director | June 17, 2019 A | 1,944,901 | 0 | 0 | $0 |
| Michael Jay Ross | Director | Oct. 1, 2018 C | 18,248 | 0 | 0 | $0 |
| Bryan V Lawlis | Director | Sept. 26, 2018 A | · | 0 | 0 | $0 |
| CELGENE CORP /DE/ | 10% owner | Oct. 1, 2018 C | 1,726,197 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 16 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.41% | 5,891 SH | Oct. 2, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.18% | 29,395 SH | Oct. 2, 2026 | Daily |
| IWC · iShares Trust | 0.07% | 53,859 SH | Sept. 11, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 11,715 SH | Aug. 19, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 91,894 SH | Aug. 19, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.01% | 21,700 SH | Oct. 2, 2026 | Daily |
| RSSL · Global X Funds | 0.01% | 7,595 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 177,152 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 47,358 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.01% | 411,674 SH | Sept. 11, 2026 | Daily |
| IWO · iShares Trust | 0.00% | 23,235 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 29,448 SH | Sept. 11, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 501,524 SH | Aug. 19, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,670 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 1,330 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 128,703 SH | Sept. 11, 2026 | Daily |
STRO Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 20 analysts
BUY
Median target
$50.00
+225.7%
6 30.0%
Strong Buy
12 60.0%
Buy
1 5.0%
Hold
1 5.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
13 analysts · 2026-10-01Mean target $47.23 +207.7%
Now
Current price $15.35
Low$10.00
Mean$47.23
High$61.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | · |
| TLSI | · | · | · | · | · | · |
| IMRX | · | -5.2 | · | · | -45.3% | · |
| ANIK | $133M | -12.6 | -5.9% | -9.6% | -7.5% | 56.6% |
| EVMN | $540M | -1.5 | 85.7% | -529.8% | -401.2% | · |
| CAMP | $318M | -2.3 | 436.5% | -2298.5% | -183.4% | · |
| PALI | $375M | -7.8 | · | · | -25.4% | · |
| GLSI | $300M | -14.7 | · | · | -2159.7% | · |
| QTTB | $43M | 1.4 | · | 55.5% | 200.3% | · |
| IVVD | $697M | -8.2 | 110.5% | -98.2% | -36.9% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 12, 2026